MedPath

Etoposide

Etoposide Injection, USP

Approved
Approval ID

fe870629-104d-4d67-a7c6-f53bc588121e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 2, 2022

Manufacturers
FDA

Fresenius Kabi USA, LLC

DUNS: 608775388

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ETOPOSIDE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63323-104
Application NumberANDA074983
Product Classification
M
Marketing Category
C73584
G
Generic Name
ETOPOSIDE
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJune 2, 2022
FDA Product Classification

INGREDIENTS (6)

BENZYL ALCOHOLInactive
Code: LKG8494WBH
Classification: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8H
Classification: IACT
POLYETHYLENE GLYCOL 300Inactive
Code: 5655G9Y8AQ
Classification: IACT
ETOPOSIDEActive
Quantity: 20 mg in 1 mL
Code: 6PLQ3CP4P3
Classification: ACTIB
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Etoposide - FDA Drug Approval Details